Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arzoxifene in Postmenopausal Bone Loss (FOUNDATION)
NCT00085956Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Arzoxifene Arm with Placebo Arm (2 arms). Primary endpoints: Bone Mineral Density at the Lumbar Spine at 24 months, Bone Mineral Density at the Total Hip at 24 months and 2 more. Started Apr 2004; status: completed.
02
Drugs
arzoxifene
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00085956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085956.